Advice
Following a full submission:
vildagliptin (Galvus) is accepted for restricted use within NHS Scotland.
Indication under review: treatment of type 2 diabetes mellitus in adults as monotherapy in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance.
SMC restriction: for use in patients for whom both metformin and sulphonylureas are inappropriate due to contraindications or intolerance.
In two comparator controlled studies the non-inferiority of vildagliptin to first-line oral anti-diabetic agents was not shown. A network meta-analysis demonstrated similar reductions in HbA1c at 24 weeks for vildagliptin versus another dipeptidyl peptidase 4 (DPP-4) inhibitor.
Download detailed advice139KB (PDF)
Medicine details
- Medicine name:
- vildagliptin (Galvus)
- SMC ID:
- 826/12
- Indication:
- As monotherapy, in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance.
- Pharmaceutical company
- Novartis Pharmaceuticals UK Ltd
- BNF chapter
- Endocrine system
- Submission type
- Full
- Status
- Restricted
- Date advice published
- 14 January 2013